PKMYT1 Promotes Epithelial-Mesenchymal Transition Process in Triple-Negative Breast Cancer by Activating Notch Signaling
- PMID: 38442372
- DOI: 10.24875/RIC.23000256
PKMYT1 Promotes Epithelial-Mesenchymal Transition Process in Triple-Negative Breast Cancer by Activating Notch Signaling
Abstract
Background: Triple-negative breast cancer (TNBC) is a subtype of breast cancer (BC) that lacks receptors for targeted therapy. Deeper insight into the molecular mechanisms regulating TNBC metastasis is urgently needed. The epithelial-mesenchymal transition process facilitates the metastasis of neighboring epithelial tumor cells. Protein kinase, membrane-associated tyrosine/threonine 1 (PKMYT1), a member of the Wee family of protein kinases, is upregulated in BC, and its high expression predicts poor prognosis in BC patients. Notch signaling activation is a pathognomonic feature of TNBC. PKMYT1 has been found to induce EMT in non-small cell lung cancer by activating Notch signaling. However, whether PKMYT1 exerts effects on TNBC progression by regulating Notch signaling remains unknown.
Objectives: The objective of this study was to investigate whether PKMYT1 exerts effects on TNBC progression by regulating Notch signaling.
Methods: Fifty cases of surgically resected BC samples (tumor and adjacent non-tumor tissue samples) were collected from patients diagnosed with BC. We measured the expression of PKMYT1 in clinical samples with real-time quantitative polymerase chain reaction (RT-qPCR). For in vitro analysis, RT-qPCR and Western blotting were conducted to evaluate PKMYT1 expression in TNBC cells. Then, the viability, migration, and invasion of TNBC cells were detected by cell counting kit-8 assays, wound healing assays, and Transwell assays. The EMT event was examined by evaluating the levels of EMT-associated proteins. For in vivo analysis, xenograft models in nude mice were established to explore PKMYT1 roles. E-cadherin and Ki67 expression in xenograft models were estimated by immunohistochemistry staining. Hematoxylin and eosin staining was performed to assess tumor metastasis. The underlying mechanisms by which PKMYT1 affected the malignant phenotypes of TNBC cells were explored by Western blotting measuring the pathway-associated proteins.
Results: PKMYT1 was upregulated in BC tissues and cells, and its knockdown prevented cell proliferation, migration, invasion, and EMT event in TNBC. Mechanistically, Notch signaling was inactivated by PKMYT1 depletion, and Notch activation abolished the PKMYT1 silencing-induced inhibition in the malignant phenotypes of TNBC cells. For in vivo analysis, PKMYT1 knockdown inhibited tumorigenesis and metastasis of TNBC.
Conclusion: PKMYT1 promotes EMT, proliferation, migration, and invasion of TNBC cells and facilitates tumor growth and metastasis by activating Notch signaling.
Keywords: Epithelial-mesenchymal transition; Metastasis; Notch; PKMYT1; Triple-negative breast cancer.
Copyright: © 2023 Permanyer.
Similar articles
-
Targeting PRDX2 to inhibit tumor growth and metastasis in triple-negative breast cancer: the role of FN1 and the PI3K/AKT/SP1 pathway.J Transl Med. 2025 Apr 11;23(1):434. doi: 10.1186/s12967-025-06441-2. J Transl Med. 2025. PMID: 40217291 Free PMC article.
-
SHP2 promotes the epithelial-mesenchymal transition in triple negative breast cancer cells by regulating β-catenin.J Cancer Res Clin Oncol. 2025 Jan 29;151(2):55. doi: 10.1007/s00432-025-06097-x. J Cancer Res Clin Oncol. 2025. PMID: 39878804 Free PMC article.
-
LINC01614 activated by SP1 promoted malignant behavior of triple-negative breast cancer cells via the WNT/b-Catenin signaling pathway.Rev Invest Clin. 2024 Oct 17;76(4):185-194. doi: 10.24875/RIC.24000093. Rev Invest Clin. 2024. PMID: 39419019
-
Triple-Negative Breast Cancer Progression and Drug Resistance in the Context of Epithelial-Mesenchymal Transition.Cancers (Basel). 2025 Jan 12;17(2):228. doi: 10.3390/cancers17020228. Cancers (Basel). 2025. PMID: 39858010 Free PMC article. Review.
-
Nanomaterials for delivery of drugs and genes to disrupt notch signaling pathway in breast cancer.Naunyn Schmiedebergs Arch Pharmacol. 2025 May 20. doi: 10.1007/s00210-025-04082-2. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40392305 Review.
Cited by
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer.Mol Cancer Ther. 2024 Oct 1;23(10):1494-1510. doi: 10.1158/1535-7163.MCT-23-0564. Mol Cancer Ther. 2024. PMID: 38781103 Free PMC article.
-
Heparan sulfate 6-O-sulfotransferase 2 promotes gastric cancer progression by modulating the TGF-β/smad2/3 pathway.Am J Transl Res. 2024 Dec 15;16(12):7924-7936. doi: 10.62347/LWZR1836. eCollection 2024. Am J Transl Res. 2024. PMID: 39822499 Free PMC article.
-
The E2F1/SBK1 axis activates the Notch signaling pathway to accelerate the malignant progression of breast cancer.Naunyn Schmiedebergs Arch Pharmacol. 2025 May 27. doi: 10.1007/s00210-025-04251-3. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40423801
-
Three-dimensional cell culture conditions promoted the Mesenchymal-Amoeboid Transition in the Triple-Negative Breast Cancer cell line MDA-MB-231.Front Cell Dev Biol. 2024 Aug 2;12:1435708. doi: 10.3389/fcell.2024.1435708. eCollection 2024. Front Cell Dev Biol. 2024. PMID: 39156975 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Molecular Biology Databases